Want to learn more about cervical cancer?

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.